Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years - Damon Bass; Regina Kurrasch; Yin Su; Jie Zheng; Yang Li; Guochun Wang; Fengchun Zhang; David A Roth; Jieruo Gu; Jenny Lowe; Myron Chu; Paula Curtis; et al. (RMD Open, 2022)